“When I think about new companies a lot of it is about timing is it too soon or too late?” Murcko notes enthusiastically in our interview. The CSO is Mark Murcko, an experienced and well known startup player. The money should get them through 3 years and a considerable de-risking approach to their preclinical efforts But asked about a timeline to proof-of-concept data, Nashat frankly estimates that it will take 4-5 years to birth some hard human data. The biotech is investing in neurodegeneration, cancer, cardiovascular and other areas for a platform that could, eventually, have extensive applications.
The Cambridge, MA-based Dewpoint team, which will now double in size over the next year, doesn’t have a late-stage preclinical program it can shove into the clinic. Hooked by the science, Arie Belldegrun joins a group of influentials who believe Dewpoint may have the key to the next big thing in biotech
